medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2020, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2020; 18 (4)

News in the Treatment of Melasma

Dagdug VAG, Guevara HC, Arellano MI

Language: Spanish
References: 60
Page: 307-317
PDF size: 163.95 Kb.


ABSTRACT

Melasma is a hyperpigmentation disorder that mainly affects women, pathogenesis factors include chronic exposure to ultraviolet radiation, visible light, hormonal stimulation and genetic factors. It is characterized by irregular, brown, reticulated spots on skin exposed areas to the sun.
Histologically, increased melanin is observed in the epidermis and/or dermis, in addition to photoaging findings, such as solar elastosis, disruption of the basement membrane, increased vascularization and an increase in the number of mast cells.
The goals in the management of melasma are: reduce the intensity of the pigment, decrease the area of the spot, prevent recurrence and improve the quality of life of the patient. First-line treatment includes the use of topical depigmenting agents, hitherto considered the gold standard, either alone or in combination to create synergy; as well as avoiding aggravating factors such as intense exposure to UVA, UVB, infrared and visible light radiation, the use of hormonal contraceptives and photosensitizing drugs.


REFERENCES

  1. Kwon SH, Na JI, Choi JY y Park KC, Melasma: updates and perspectives, Exp Dermatol 2018; 28(6):704-8.

  2. Spierings NMK, Melasma: a critical analysis of clinical trials investigating treatment modalities published in the past 10 years, J Cosmet Dermatol 2019;19(6):1284-9.

  3. Mckesey J, Tovar-Garza A y Pandya AG, Melasma treatment: an evidence- based review, Am J Clin Dermatol 2019; 21(2):173-225.

  4. Fioranelli M, Jafferany M, Wollina U, Tirant M, Thuong NV y Lotti T, New local treatments for different types of melasma: vascular type vs. nonvascular type. A randomized polycentric study, Dermatol Ther 2020; 33(3).

  5. Kwon S-H, Hwang Y-J, Lee S-K y Park K-C, Heterogeneous pathology of melasma and its clinical implications, Int J Mol Sci 2016; 17(6):824.

  6. Zhou LL y Baibergenova A, Melasma: systematic review of the systemic treatments, Int J Dermatol 2017; 56(9):902-8.

  7. Atefi N, Dalvand B, Ghassemi M, Mehran G y Heydarian A, Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma, Dermatol Ther 2017; 7(3):417-24.

  8. Trivedi M, Yang F y Cho B, A review of laser and light therapy in melasma, Int J Womens Dermatol 2017; 3(1):11-20.

  9. Ogbechie-Godec OA y Elbuluk N, Melasma: an up-to-date comprehensive review, Dermatol Ther 2017; 7(3):305-18.

  10. Nomakhosi M y Heidi A, Natural options for management of melasma, a review, J Cosmet Laser Ther 2018; 20(7-8):470-81.

  11. Grimes P, Ijaz S, Nashawati R y Kwak D, New oral and topical approaches for the treatment of melasma, Int J Womens Dermatol 2019; 5(1):30-6.

  12. Bala HR, Lee S, Wong C, Pandya A y Rodrigues M, Oral tranexamic acid for the treatment of melasma, Dermatol Surg 2018; 44(6):814-25.

  13. Passeron T, Genedy R, Salah L, Fusade T, Kositratna G, Laubach HJ et al., Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology, J Eur Acad Dermatol Venereol 2019; 33(6):987-1005.

  14. Zubair R, Lyons AB, Vellaichamy G, Peacock A y Hamzavi I, What’s new in pigmentary disorders, Dermatol Clin 2019; 37(2):175-81.

  15. Yi J, Hong T, Zeng H, Li P, Li P, Wang S et al., A meta-analysis-based assessment of intense pulsed light for treatment of melasma, Aesthetic Plast Surg 2020; 44(3):947-52.

  16. Ali FR, Oral tranexamic acid for the treatment of melasma, Clin Exp Dermatol 2018; 44(3):347-9.

  17. Alster TS y Graham PM, Microneedling, Dermatol Surg 2018; 44(3): 397-404.

  18. Colferai MMT, Miquelin GM y Steiner D, Evaluation of oral tranexamic acid in the treatment of melasma, J Cosmet Dermatol 2018; 18(5):1495-501.

  19. Gan WLTE, Double blind placebo controlled trial to evaluate of the effectiveness of a dietary supplement rich in carotenoids as adjunct to topical lightening cream for the treatment of melasma: a pilot study, J Pigment Disord 2015; 02(02).

  20. Nestor MS, Berman B y Swenson N, Safety and efficacy of oral polypodium leucotomos extract in healthy adult subjects, J Clin Aesthet Dermatol 2015; 8(2):19-23.

  21. Kurmus G, Tatlıparmak A, Aksoy B, Koç E, Serdar ZA y Ergin C, Efficacy and safety of 1927 nm fractional thulium fiber laser for the treatment of melasma: a retrospective study of 100 patients, J Cosmet Laser Ther 2019; 21(7-8):408-11.

  22. Berardesca E, Rigoni C, Cantù A, Cameli N, Tedeschi A, Laureti T et al., Effectiveness of a new cosmetic treatment for melasma, J Cosmet Dermatol 2019; 19(7):1684-90.

  23. Zhu CY, Li Y, Sun QN, Takada A y Kawada A, Análisis del efecto de diferentes dosis de ácido tranexámico oral en el melasma: un estudio prospectivo multicéntrico, Eur J Dermatol 2019; 29(1):55-8.

  24. Sarkar R, Arsiwala S, Dubey N, Sidharth Sonthalia, Anupam Das, Latika Arya et al., Chemical peels in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group, Indian J Dermatol 2017; 62(6):578-84.

  25. Rajanala S, Maymone MBC y Vashi NA, Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies, Dermatol Online J 2019; 25(10):13030/qt47b7r28c.

  26. Taghavi F, Banihashemi M, Zabolinejad N, Salehi M, Jaafari MR, Marhamati H et al., Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma, J Cosmet Dermatol 2018; 18(3):870-3.

  27. Ismail ESA, Patsatsi A, El-Maged WMA, Nada EDAA, Efficacy of microneedling with topical vitamin c in the treatment of melasma, J Cosmet Dermatol 2019; 18(5):1342-7.

  28. Sarma N, Chakraborty S, Poojary SA, Sanjay Rathi, Sendhil Kumaran, Balakrishnan Nirmal et al., Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma, Indian Dermatol Online J 2017; 8(6):406-42.

  29. Sarkar R, Ailawadi P y Garg S, Melasma in men: a review of clinical, etiological, and management issues, J Clin Aesthet Dermatol 2018; 11(2):53-9.

  30. Jin Y, Jiang W, Yao Y, Huang H y Huang J, Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study, Laser Med Sci 2019; 34(6):1099-105.

  31. Kim SJ, Park J-Y, Shibata T, Fujiwara R y Kang HY, Efficacy and possible mechanisms of topical tranexamic acid in melasma, Clin Exp Dermatol 2016; 41(5):480-5.

  32. Kwon SH, Na JI, Choi JY y Park KC, Melasma: updates and perspectives, Exp Dermatol 2019; 28(6):704-8.

  33. Sarkar R, Aurangabadkar S, Salim T, Anupam D, Swapnil S, Imran M et al., Lasers in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group, Indian J Dermatol 2017; 62(6):585-90.

  34. Lima EDA, Microneedling in facial recalcitrant melasma: report of a series of 22 cases, An Bras Dermatol 2015; 90(6):919-21.

  35. Rodrigues M y Pandya AG, Melasma: clinical diagnosis and management options, Aust J Dermatol 2015; 56(3):151-63.

  36. Sarkar R, Garg V, Bansal S, Sethi S y Gupta C, Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma, Dermatol Surg 2016; 42(3):384-91.

  37. Taraz M, Niknam S y Ehsani AH, Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies, Dermatol Ther 2017; 30(3).

  38. Truchuelo M, Cerdá P y Fernández L, Peeling químico, una herramienta útil en la consulta, Actas Dermosifiliogr 2017; 108(4):315-22.

  39. Sheu SL, Treatment of melasma using tranexamic acid: what’s known and what’s next, Cutis 2018; 101(2):E7-E8.

  40. Fatima S, Braunberger T, Mohammad TF, Kohli I y Hamzavi IH, The role of sunscreen in melasma and postinflammatory hyperpigmentation, Indian J Dermatol 2020; 65(1):5-10.

  41. Del Rosario ED, Florez-Pollack S, Zapata L, Hernández K, Tovar-Garza A, Rodrigues M et al., Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma, J Am Acad Dermatol 2018; 78(2):363-9.

  42. Juhasz MLW y Levin MK, The role of systemic treatments for skin lightening, J Cosmet Dermatol 2018; 17(6):1144-57.

  43. Lima EVA, Lima MMDA, Paixão MP y Miot HA, Assessment of the effects of skin microneedling as adjuvant therapy for facial melasma: a pilot study, bmc Dermatol 2017; 17(1).

  44. Ramaut L, Hoeksema H, Pirayesh A, Stillaert F y Monstrey S, Microneedling: where do we stand now? A systematic review of the literatura, J Plast Reconstr Aesth 2018; 71(1):1-14.

  45. Passeron T y Picardo M, Melasma, a photoaging disorder, Pigment Cell Melanoma Res 2018; 31(4):461-5.

  46. Zhang Y, Zheng X, Chen Z y Lu L, Laser and laser compound therapy for melasma: a meta-analysis, J Dermatolog Treat 2019; 31(1):77-83.

  47. Bagherani N y Smoller BR, Efficacy of topical tranexmic acid in the treatment of melasma, Dermatol Ther 2016; 29(6):389-90.

  48. Boukari F, Jourdan E, Fontas E, Montaudié H, Castela E, Lacour J-P et al., Prevention of melasma relapses with sunscreen combining protection against uv and short wavelengths of visible light: a prospective randomized comparative trial, J Am Acad Dermatol 2015; 72(1).

  49. Chalermchai T y Rummaneethorn P, Effects of a fractional picosecond 1 064 nm laser for the treatment of dermal and mixed type melasma, J Cosmet Laser Ther 2017; 20(3):134-9.

  50. Wang JV, Jhawar N y Saedi N, Tranexamic acid for melasma: evaluating the various formulations, J Clin Aesthet Dermatol 2019; 12(8):E73-E74.

  51. Arellano Mendoza I, Ocampo Candiani JJ, Rodríguez Castellanos MA, Jesús Silva MA, Estrada Aguilar L et al., Guías de diagnóstico y manejo de melasma, Dermatología cmq 2017; 16(1):12-23.

  52. Shah S y Aurangabadkar S, Laser toning in melasma, J Cutan Aesthet Surg 2019;12(2):76.

  53. Lee HC, Thng TGS y Goh CL, Oral tranexamic acid (ta) in the treatment of melasma: a retrospective analysis, J Am Acad Dermatol 2016; 75(2):385-92.

  54. Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T y Kolbe L, Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma, J Invest Dermatol 2019; 139(8).

  55. Mazurek K y Pierzchała E, Comparison of efficacy of products containing azelaic acid in melasma treatment, J Cosmet Dermatol 2016; 15(3):269-82.

  56. Gong Z, Lai W, Zhao G, Wang X, Zheng M, Li L et al., Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo- controlled, multicenter, parallel-group study, Clin Drug Invest 2015; 35(6):385-95.

  57. Kasraee B, Mansouri P y Farshi S, Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligmans formula, J Cosmet Dermatol 2018; 18(1):293-5.

  58. Lajevardi V, Ghayoumi A, Abedini R et al., Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor-and analyst-blinded, randomized controlled trial with a short-term follow-up, J Cosmet Dermatol 2017; 16(2):235-42.

  59. Padhi T y Pradhan S, Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial, Indian J Dermatol 2015; 60(5):520. doi:10.4103/0019-5154.164416.

  60. Lyons AB, Trullas C, Kohli I, Hamzavi IH y Lim HW, Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens, J Am Acad Dermatol 2020; S0190-9622(20)30694-0.




2020     |     www.medigraphic.com